Back to Search
Start Over
Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach.
- Source :
-
PloS one [PLoS One] 2021 Feb 03; Vol. 16 (2), pp. e0245072. Date of Electronic Publication: 2021 Feb 03 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Middle East respiratory syndrome (MERS-COV), first identified in Saudi Arabia, was caused by a novel strain of coronavirus. Outbreaks were recorded from different regions of the world, especially South Korea and the Middle East, and were correlated with a 35% mortality rate. MERS-COV is a single-stranded, positive RNA virus that reaches the host by binding to the receptor of dipeptidyl-peptides. Because of the unavailability of the vaccine available for the protection from MERS-COV infection, the rapid case detection, isolation, infection prevention has been recommended to combat MERS-COV infection. So, vaccines for the treatment of MERS-COV infection need to be developed urgently. A possible antiviral mechanism for preventing MERS-CoV infection has been considered to be MERS-CoV vaccines that elicit unique T-cell responses. In the present study, we incorporated both molecular docking and immunoinformatic approach to introduce a multiepitope vaccine (MEP) against MERS-CoV by selecting 15 conserved epitopes from seven viral proteins such as three structural proteins (envelope, membrane, and nucleoprotein) and four non-structural proteins (ORF1a, ORF8, ORF3, ORF4a). The epitopes, which were examined for non-homologous to host and antigenicity, were selected on the basis of conservation between T-cell, B-cell, and IFN-γ epitopes. The selected epitopes were then connected to the adjuvant (β-defensin) at the N-terminal through an AAY linker to increase the immunogenic potential. Structural modelling and physiochemical characteristic were applied to the vaccine construct developed. Afterwards the structure has been successfully docked with antigenic receptor, Toll-like receptor 3 (TLR-3) and in-silico cloning ensures that its expression efficiency is legitimate. Nonetheless the MEP presented needs tests to verify its safety and immunogenic profile.<br />Competing Interests: The authors have declared that no competing interests exist.
- Subjects :
- Amino Acid Sequence
Binding Sites
Coronavirus Infections immunology
Coronavirus Infections pathology
Coronavirus Infections prevention & control
Drug Design
Epitopes chemistry
Humans
Molecular Docking Simulation
Protein Structure, Secondary
Protein Structure, Tertiary
Vaccines, Subunit chemistry
Vaccines, Subunit immunology
Viral Nonstructural Proteins chemistry
Viral Nonstructural Proteins immunology
Viral Structural Proteins chemistry
Viral Structural Proteins immunology
Viral Vaccines chemistry
Epitopes immunology
Middle East Respiratory Syndrome Coronavirus metabolism
Proteome
Viral Vaccines immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 16
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 33534822
- Full Text :
- https://doi.org/10.1371/journal.pone.0245072